BioSpace News Archive

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company held a Type A meeting with the U.S. Food and Drug Administration during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter received in February.

Translational Research in Oncology, a global academic clinical research organization, announced enrolment completion in coopERA Breast Cancer, a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant sponsored by F. Hoffmann-La Roche.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it has dosed the first acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced positive safety results from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.

Biomet Holdings, Inc. announced its second quarter earnings conference call will be webcast on Tuesday, August 3, 2021 at 8:30 a.m. ET.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company’s Biologics License Application for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals.

Treo Ventures portfolio company CVRx, Inc. announced the upsized pricing of its initial public offering on the Nasdaq Global Select Market.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 16,250 shares of its common stock and the grant of 8,125 restricted stock units to three new employees.

uLab Systems™, the creator of uSmile™ Clear Aligners, has raised $54.5 million in its oversubscribed Series E financing round

The report highlights the key factors driving the market growth and prominent players with their developments in the market.